Search research articles
Contact Us
Filters
Showing results (431-440 of 493) with videos related to
Page
of 50
Sort By:
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Annals of Surgical Oncology
|
July 11, 2013
Age as a prognostic factor in patients with localized melanoma and regional metastases
Charles M Balch, Seng-jaw Soong, Jeffrey E Gershenwald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Miriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F McDermott, Charles G Drake, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Thomas Denize, Opeyemi A Jegede, Sayed Matar, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.
Cancer Immunology Research
|
May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.
Page
of 50
Search research articles
Search
Showing results (431-440 of 493) with videos related to
Sort By:
Page
of 50
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Annals of Surgical Oncology
|
July 11, 2013
Age as a prognostic factor in patients with localized melanoma and regional metastases
Charles M Balch, Seng-jaw Soong, Jeffrey E Gershenwald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Miriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F McDermott, Charles G Drake, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Thomas Denize, Opeyemi A Jegede, Sayed Matar, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.
Cancer Immunology Research
|
May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.
Page
of 50